23.54  2.025 (9.41%)		03-20 16:00
Open: 20.64 High: 23.8 Volume: 24,773		Pre. Close: 21.515 Low: 20.64 Market Cap: 1,033(M)

Short term
Mid term
Targets	6-month :	30.99	1-year :	35.61
Resists	First :	26.53	Second :	30.48
Pivot price	22.15
Supports	First :	20.13	Second :	16.75
MAs	MA(5) :	21.86	MA(20) :	23.03
	MA(100) :	26.58	MA(250) :	26.77
MACD	MACD :	-1.1	Signal :	-1.3
%K %D	K(14,3) :	26.3	D(3) :	16.7
RSI	RSI(14): 50.3
52-week	High :	55.65	Low :	5.88

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NNNN ] has closed below upper band by 15.6%. Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	23.82 - 23.91	23.91 - 24.02
Low:	20.42 - 20.51	20.51 - 20.61
Close:	23.36 - 23.51	23.51 - 23.7

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Fri, 21 Feb 2025
Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Thu, 20 Feb 2025
NNNN - ANBIO BIOTECHNOLOGY Latest Stock News & Market Updates - Stock Titan

Thu, 20 Feb 2025
Fresh Biotech Player Enters Nasdaq: Will Anbio's $8M IPO Fuel Its Global Expansion? - Stock Titan

Wed, 19 Feb 2025
Anbio Biotechnology’s IPO opens up 5% By Investing.com - Investing.com India

Tue, 18 Feb 2025
NNNN Stock Price and Chart — NASDAQ:NNNN - TradingView

Mon, 04 Oct 2021
Talkspace - TALK - Stock Price & News - The Motley Fool

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	44 (M)
Shares Float	40 (M)
Held by Insiders	4.7 (%)
Held by Institutions	4.8 (%)
Shares Short	52 (K)
Shares Short P.Month	51 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.62
Profit Margin	37.2 %
Operating Margin	73.4 %
Return on Assets (ttm)	4.7 %
Return on Equity (ttm)	11.1 %
Qtrly Rev. Growth	-21.7 %
Gross Profit (p.s.)	0.14
Sales Per Share	0.15
EBITDA (p.s.)	0
Qtrly Earnings Growth	2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	392.33
PEG Ratio	0
Price to Book value	37.36
Price to Sales	149.3
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.